Single‐Dose Liposomal Amphotericin B in the Treatment of Visceral Leishmaniasis in India: A Multicenter Study
Open Access
- 15 September 2003
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 37 (6), 800-804
- https://doi.org/10.1086/377542
Abstract
Widespread antimony resistance renders conventional amphotericin B the only option for the treatment of visceral leishmaniasis (VL) in North Bihar, IKeywords
This publication has 21 references indexed in Scilit:
- Oral Miltefosine for Indian Visceral LeishmaniasisNew England Journal of Medicine, 2002
- Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial Commentary: cost and resistance remain issuesBMJ, 2001
- Treatment of visceral leishmaniasisMedical Microbiology and Immunology, 2001
- Failure of Pentavalent Antimony in Visceral Leishmaniasis in India: Report from the Center of the Indian EpidemicClinical Infectious Diseases, 2000
- Miltefosine, an Oral Agent, for the Treatment of Indian Visceral LeishmaniasisNew England Journal of Medicine, 1999
- Cure of Antimony-Unresponsive Indian Visceral Leishmaniasis with Amphotericin B Lipid ComplexThe Journal of Infectious Diseases, 1996
- Clinicoepidemiological study of drug resistance in Indian kala - azarBMJ, 1994
- Assessing the Reliability of Two Toxicity Scales: Implications for Interpreting Toxicity DataJNCI Journal of the National Cancer Institute, 1993
- Amphotericin B for second-line treatment of Indian kala-azarThe Lancet, 1991
- Quantitation of Amastigotes of Leishmania Donovani in Smears of Splenic Aspirates from Patients with Visceral Leishmaniasis *The American Journal of Tropical Medicine and Hygiene, 1983